Growth suppression of human laryngeal squamous cell carcinoma by adenovirus-mediated tissue factor pathway inhibitor gene 2

Laryngoscope

Volumn 116, Issue 4, 2006, Pages 596-601

  Sun, Yanan ^a,b   Xie, Minqiang ^b   Liu, Ming ^a   Jin, Dejun ^a   Li, Peng ^b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Gene therapy; Laryngeal squamous cell carcinoma; Recombinant adenovirus; Tissue factor pathway inhibitor gene 2

Indexed keywords

ADENOVIRUS VECTOR; BETA LACTAMASE; CYCLINE; PLACENTA PROTEIN 5; RECOMBINANT DNA; BLOOD CLOTTING FACTOR 7A; GLYCOPROTEIN; SERINE PROTEINASE INHIBITOR; TISSUE-FACTOR-PATHWAY INHIBITOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INFRARED SPECTROSCOPY; LARYNX CARCINOMA; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZATION; SQUAMOUS CELL CARCINOMA; TUMOR CELL; TUMOR VOLUME; ULTRASTRUCTURE; VIRAL GENE THERAPY; WESTERN BLOTTING; XENOTRANSPLANTATION; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; COMPARATIVE STUDY; DRUG ANTAGONISM; GENE THERAPY; GENE VECTOR; GENETICS; LARYNX TUMOR; METABOLISM; METHODOLOGY; PATHOLOGY; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; FACTOR VIIA; GENE THERAPY; GENETIC VECTORS; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LARYNGEAL NEOPLASMS; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, TRANSMISSION; PROLIFERATING CELL NUCLEAR ANTIGEN; SERINE PROTEINASE INHIBITORS;

EID: 33645915731     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlg.0000205589.84020.d2     Document Type: Article

References (23)

1. Strome SE, Weinman EC. Advanced larynx cancer. Curr Treat Options Oncol 2002;3:11-20.
2. Almadori G, Bussu F, Cadoni G, et al. Molecular markers in laryngeal squamous cell carcinoma: towards an integrated clinicobiological approach. Eur J Cancer 2005;41:683-693.
3. Xie M, Sun Y, Li Y. Expression of matrix metalloproteinases in supraglottic carcinoma and its clinical implication for estimating lymph node metastases. Laryngoscope 2004;114:2243-2248.
4. Hojilla CV, Mohammed FF, Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 2003;89:1817-1821.
5. Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 2004;23:101-117.
6. Chand HS, Du X, Ma D, et al. The effect of human tissue factor pathway inhibitor-2 on the growth and metastasis of fibrosarcoma tumors in athymic mice. Blood 2004;103:1069-1077.
7. Crowe DL, Shuler CF. Regulation of tumor cell invasion by extracellular matrix. Histol Histopathol 1999;14:665-671.
8. McCawley LJ, Matrisian LM. Matrix metalloproteinases: multifunctional contributors to tumor progression. Mol Med Today 2000;6:149-156.
9. Nabeshima K, Inoue T, Shimao Y, et al. Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int 2002;52:255-264.
10. Hornebeck W, Emonard H, Monboisse JC, et al. Matrix-directed regulation of pericellular proteolysis and tumor progression. Semin Cancer Biol 2002;12:231-241.
11. Rao CN, Mohanam S, Puppala A, et al. Regulation of ProMMP-1 and ProMMP-3 activation by tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor. Biochem Biophys Res Commun 1999;255:94-98.
12. Rao CN, Reddy P, Liu Y, et al. Extracellular matrix-associated serine protease inhibitors (Mr 33,000, 31,000, and 27,000) are single-gene products with differential glycosylation: cDNA cloning of the 33-kDa inhibitor reveals its identity to tissue factor pathway inhibitor-2. Arch Biochem Biophys 1996;335:82-92.
13. Liu YY, Stack SM, Lakka SS, et al. Matrix localization of tissue factor pathway inhibitor-2/matrix-associated serine protease inhibits (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: heparin accelerates the activity of TFPI-2/MSPI toward plasmin. Arch Biochem Biophys 1999;370:112-118.
14. Miyagi Y, Yasumitsu H, Miyata S, et al. Assignment of the human PP5/TFPI-2 gene to 7Q 22 by FISH and PCR-based human mapping panel analysis. Genomics 1996;35:267-268.
15. Rao CN, Lakka SS, Kin Y, et al. Expression of tissue factor pathway inhibitor 2 inversely correlates during the progression of human gliomas. Clin Cancer Res 2001;7:570-576.
16. Rollin J, Iochmann S, Blechet C, et al. Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer. Br J Cancer 2005;92:775-83.
17. Sato N, Parker AR, Fukushima N, et al. Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene 2005;24:850-858.
18. Konduri SD, Tasiou A, Chandrasekar N, et al. Role of tissue factor pathway inhibitor-2 (TFPI-2) in amelanotic melanoma (C-32) invasion. Clin Exp Metastasis 2000;18:303-308.
19. Moon C, Oh Y, Roth JA. Current status of gene therapy for lung cancer and head and neck cancer. Clin Cancer Res 2003;9:5055-67.
20. Wojtukiewicz MZ, Sierko E, Zimnoch L, et al. Immunohistochemical localization of tissue factor pathway inhibitor-2 in human tumor tissue. Thromb Haemost 2003;90:140-146.
21. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 2001;13:534-540.
22. Tasiou A, Konduri SD, Yanamandra N, et al. A novel role of tissue factor pathway inhibitor-2 in apoptosis of malignant human gliomas. Int J Oncol 2001;19:591-597.
23. Lynch CC, Matrisian LM. Matrix metalloproteinases in tumor-host cell communication. Differentiation 2002;70:561-573.